Data gathered: November 1
Alternative Data for Verrica Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Google Trends | 7 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,214 | Sign up | Sign up | Sign up |
| Twitter Mentions | 14 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc., a dermatological therapy company, develops and markets treatments for people with skin conditions in the United States. The company is headquartered in West Chester, Pennsylvania.
| Price | $1.40 |
| Target Price | Sign up |
| Volume | 265,360 |
| Market Cap | $71M |
| Year Range | $1.11 - $9.56 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Verrica Pharmaceuticals Inc. Investor Alert (NASDAQ: VRCA)October 29 - Finnhub |
|
 |
Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Increases By 24.8%October 28 - Biztoc.com |
 |
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Consensus Recommendation of “Moderate Buy” by BrokeragesOctober 28 - ETF Daily News |
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology ConferenceOctober 24 - GlobeNewswire |
|
 |
Verrica Pharmaceuticals (NASDAQ:VRCA) PT Lowered to $10.00 at TD CowenOctober 23 - ETF Daily News |
|
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Rating of "Moderate Buy" from AnalystsOctober 21 - Biztoc.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '24 | 5.2M | 700,000 | 4.5M | -17M | -15M | -0.370 |
| Q1 '24 | 1.5M | 700,000 | 810,000 | -20M | -18M | -0.440 |
| Q4 '23 | 2M | 200,000 | -3M | -25M | -23M | -0.530 |
| Q3 '23 | 1.3M | 300,000 | 960,000 | -25M | -24M | -0.540 |
| Q2 '23 | 180,000 | 5.9M | -5.8M | -11M | -11M | -0.240 |
Insider Transactions View All
| White Ted filed to sell 215,967 shares at $2.5. August 28 '24 |
| Kohler Terry filed to sell 44,697 shares at $2.5. August 28 '24 |
| Bonaccorso Joe filed to sell 73,114 shares at $2.5. August 28 '24 |
| Goldenberg Gary filed to sell 94,261 shares at $2.5. August 28 '24 |
| Hayes Christopher G. filed to sell 105,773 shares at $2.5. August 28 '24 |
Similar companies
Read more about Verrica Pharmaceuticals (VRCA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Verrica Pharmaceuticals?
The Market Cap of Verrica Pharmaceuticals is $71M.
What is the current stock price of Verrica Pharmaceuticals?
Currently, the price of one share of Verrica Pharmaceuticals stock is $1.40.
How can I analyze the VRCA stock price chart for investment decisions?
The VRCA stock price chart above provides a comprehensive visual representation of Verrica Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Verrica Pharmaceuticals shares. Our platform offers an up-to-date VRCA stock price chart, along with technical data analysis and alternative data insights.
Does VRCA offer dividends to its shareholders?
As of our latest update, Verrica Pharmaceuticals (VRCA) does not offer dividends to its shareholders. Investors interested in Verrica Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Verrica Pharmaceuticals?
Some of the similar stocks of Verrica Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.